Glas, Martin <br/><br/>
Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma.  [electronic resource] 

 -  Stem cells (Dayton, Ohio)  Jun 2013 
 - 1064-74 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1549-4918 
<br/><br/><label>Standard No.: </label>10.1002/stem.1350  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Brain Neoplasms--drug therapy<br/>Cell Line, Tumor<br/>Cytosol--drug effects<br/>DEAD Box Protein 58<br/>DEAD-box RNA Helicases--genetics<br/>Glioblastoma--drug therapy<br/>Humans<br/>Immunity, Innate--drug effects<br/>Interferon-Induced Helicase, IFIH1<br/>Ligands<br/>Receptors, Immunologic<br/>Signal Transduction--drug effects<br/>Stem Cells--drug effects